Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S200-S216

  Mahon, Robert N ^a   Hafner, Richard ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

host directed therapy; immunometabolism; precision medicine; signaling pathways; Tuberculosis

Indexed keywords

GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SIRTUIN; MTOR PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARP1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUBERCULOSTATIC AGENT;

ARTICLE; AUTOPHAGY; CELL FUNCTION; CELL STRESS; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC CELL; HOST; HOST RESISTANCE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUBERCULOSIS; UNFOLDED PROTEIN RESPONSE; WNT SIGNALING PATHWAY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PERSONALIZED MEDICINE; PROCEDURES;

AMP-ACTIVATED PROTEIN KINASES; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES; PRECISION MEDICINE; SIGNAL TRANSDUCTION; SIRTUINS; TOR SERINE-THREONINE KINASES; TUBERCULOSIS;

EID: 84943380478     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ621     Document Type: Article

References (210)

1. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015; 15:255-63.
2. Mathis D, Shoelson E. Immunometabolism: an emerging frontier. Nat Rev Immunol 2011; 11:81-3.
3. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13:679-92.
4. Stamm CE, Collins AC, Shiloh MU. Sensing of Mycobacterium tuberculosis and consequences to both host and bacillus. Immunol Rev 2015; 264:204-19.
5. Richardson ET, Shukla S, Sweet DR, et al. TLR2-dependent ERK signaling in Mycobacterium tuberculosis-infected macrophages drives anti-inflammatory responses and inhibits Th1 polarization of responding T cells. Infect Immun 2015; 83:2242-54.
6. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9.
7. Plantevin Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012; 22:1433-8.
8. Samatar AA, Poulikakos PI. Targeting RAS-ERK signaling in cancer: promises and challenges. Nat Rev Drug Discov 2014; 13:928-42.
9. Pan P, Shen M, Yu H, Li Y, Li D, Hou T. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today 2013; 18:1323-33.
10. Stieglitz E, Ward AF, Gerbing RB, et al. Phase II/III trial of a pretransplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the children's oncology group. Pediatr Blood Cancer 2015; 62:629-36.
11. Badar T, Cortes JE, Ravandi F, et al. Phase I study of S-trans, transfarnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk 2015; 15:433-8.
12. Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 2013; 62:341-54.
13. Sawada N, Liao JK. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal 2014; 20:1251-67.
14. Liu Y, Huang C, Ceng C, Zhan H, Zheng D, Han W. Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia. Lipids Health Dis 2014; 13:115.
15. Song L, Li Y, He B, Gong Y. Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer. Clin Colorectal Cancer 2015; 14:133-45.
16. Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 2015; 146:1-11.
17. Kulak O, Chen H, Holohan B, et al. Disruption of Wnt/-catenin signaling and telomeric shortening are inextricable consequences of tankyrase inhibition in human cells. Mol Cell Biol 2015; 35: 2425-35.
18. Koval AV, Vlasov P, Shichkova P, et al. Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling. Biochem Pharmacol 2014; 87:571-8.
19. Rask-Anderson M, Zhang UJ, Fabbro D, Schiöth HB. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 2014; 35:604-20.
20. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015; 36:422-39.
21. Napier RJ, RafiW, Cheruvu M, et al. Imatinib-sensitive tyrosine kinase regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011; 10:475-85.
22. Napier RJ, Norris BA, Swimm A, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015; 11:e1004770.
23. Maiga M, Ahidjo BA, Maiga MC, et al. Efficacy of adjunctive tofacitinib therapy in mouse models of tuberculosis. EBioMedicine 2015; doi:10.1016/j.ebiom.2015.07.014.
24. Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signaling limits mycobacterial growth. Nature 2014; 517: 512-615.
25. Stanley SA, Barczak AK, Silvis MR, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 2014; 10:e1003946.
26. Ozanne J, Prescott AR, Clark K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem J 2015; 465:271-9.
27. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes Diabetes Metab Syndr Obes 2014; 7:241-53.
28. Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Trans Med 2014; 6:263-159.
29. Yang CS, Kim JJ, Lee HM, et al. The AMPK-PPARGC1A pathway is required for antimicrobial host defense through activation of autophagy. Autophagy 2014; 10:785-802.
30. Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: from mechanism of action to clinical studies. Biochem Cell Biol 2014; 1:1-8.
31. Inoue H, Nakata R. Resveratrol targets in inflammation. Endocr Metab Immune Disord Drug Targets 2015; 15:1-10.
32. Chung SS. A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures. Ther Adv Neurol Disord 2015; 8:131-6.
33. Ko D, Yang H, Williams B, Xing D, Laurenza A. Perampanel in the treatment of partial seizures: time to onset and duration of most common adverse events from pooled phase III and extension studies. Epilepsy Behav 2015; 48:45-52.
34. Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 2015; 12:27-41.
35. Banasik M, Stedeford T, Strosznajder RP. Natural inhibitors of poly (ADP-ribose) polymerase-1. Mol Neurobiol 2012; 46:55-63.
36. Sinclair DA, Guarente L. Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 2014; 54:363-80.
37. Hu J, Jing H, Lin H. Sirtuin inhibitors as anticancer agents. Future Med Chem 2014; 6:945-66.
38. Du G, Song Y, Zhang T, et al. Simvastatin attenuates TNF-induced apoptosis in endothelial progenitor cells via the upregulation of SIRT1. Int J Mol Med 2014; 34:177-82.
39. Bertacchini J, Heidari N, Mediani L, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci 2015; 72:2337-47.
40. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015; 36:124-35.
41. Huang Z, Wu Y, Zhou X, et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol 2015; 11: 1687-99.
42. Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res 2014; 16:203.
43. Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood 2014; 124:2190-5.
44. Friedman DR, Lanasa MC, Davis PH, et al. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies. Leuk Lymphoma 2014; 55:1067-75.
45. Ramanathan RK, McDonough SH, Kennecke HF, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer 2015; 121:2193-7.
46. Cani A, Simioni C, Martelli AM, et al. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget 2015; 6:6597-610.
47. Sampath D, Malik A, Plunkett W, et al. Phase I clinical, pharmacokinetic, and pharmacodynamics study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 2013; 37:1461-7.
48. Chen G, Tang J, Ni Z, et al. Antiasthmatic effects of resveratrol in ovalbumin-induced asthma model mice involved in the upregulation of PTEN. Biol Pharm Bull 2015; 38:507-13.
49. Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011; 17: 569-77.
50. Levine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. J Clin Invest 2015; 125:14-24.
51. Ramprasath T, Vasudevan V, Sasikumar S, Puhari SS, Saso L, Selvam GS. Regression of oxidative stress by targeting eNOS and Nrf/ARE signaling: a guided drug target for cardiovascular diseases. Curr Top Med Chem 2015; 15:857-71.
52. Ebrahimpour Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M. Effects of Silybum marianum (L.) Gaertn. (silymarin) extracts supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine 2015; 22:290-6.
53. Hu H, Zhai C, Qian G, et al. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression and inflammatory reaction. Pharm Biol 2015; 13: 1-7.
54. Levy M, Thaiss CA, Elinav E. Taming the inflammasome. Nat Med 2015; 21:213-5.
55. Lenin R, Maria MS, Agrawal M, Balasubramanyam J, Mohan V, Balasubramanyam M. Amelioration of glucolipotoxicity-induced endoplasmic reticulum stress by a "chemical chaperone" in human THP-1 monocytes. Exp Diabetes Res 2012; doi:10.1155/2012/356487.
56. Li JS, Wang WJ, Sun Y, Zhang YH, Zheng L. Ursolic acid inhibits the development of nonalcoholic fatty liver disease by attenuating endoplasmic reticulum stress. Food Funct 2015; 6:1643-51.
57. Kawanami D, Matoba K, Okada R, et al. Fasudil inhibits ER stressinduced VCAM-1 expression by modulating unfolded protein response in endothelial cells. Biochem Biophys Res Commun 2013; 435:171-5.
58. Gani AR, Uppala JK, Ramaiah KV. Tauroursodeoxycholic acid prevents stress induced aggregation of proteins in vitro and promotes PERK activation in HepG2 cells. Arch Biochem Biophys 2015; 568: 8-15.
59. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21:263-9.
60. Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21:248-55.
61. Passos-Silva DG, Brandan E, Santos RA. Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol Sci 2015; 36:310-20.
62. Lee WJ, Ou HC, Hsu WC, et al. Ellagic acid inhibits oxidized LDLmediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J Vasc Surg 2010; 52:1290-300.
63. Tsai KL, Chen LH, Chiou SH, et al. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1 mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. Mol Nutr Food Res 2011; 55(suppl 2): S227-40.
64. Yamagata K, Tusruta C, Ohtuski A, Tagami M. Docosahexaenoic acid decreases TNF-induced lectin-like oxidized low-density lipoprotein receptor-1 expression in THP-1 cells. Prostaglandins Lekot Essent Fatty Acids 2014; 90:125-32.
65. Zhang L, Cheng L, Wang Q, et al. Atorvastatin protects cardiomyocytes from oxidative stress by inhibiting LOX-1 expression and cardiomyocyte apoptosis. Acta Biochim Biophys Sin 2015; 47:174-82.
66. Li XB, Cheng X, Zhang DL, et al. Syntheses of tanshinone anhydrides and their suppression on oxidized LDL uptake in macrophages and foam cell formation. Pharmazie 2014; 69:163-7.
67. Guerra GC, Araújo AA, Lira GA, et al. Telmisartan decreases inflammation by modulating TNF-, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacol Rep 2015; 67:520-6.
68. Guo C, Sinnott B, Niu B, Lowry MB, Fantacone ML, Gombart AF. Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. Mol Nutr Food Res 2014; 58:528-36.
69. Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antiinflammatory action. J Clin Endocrinol Metab 2012; 97:3333-41.
70. Nussbaumer O, Gruenbacher G, Gander H, Komuczki J, Rahm A, Thurnher M. Essential requirement of zoledronate-induced cytokine and T cell proliferative responses. J Immunol 2013; 191:1346-55.
71. Naraoka M, Munakata A, Matsuda N, Shimamura N, Ohkuma H. Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit. Transl Strok Res 2013; 4:368-74.
72. Mily A, Rekha RS, Kamal SM, et al. Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis. BMC Pulm Med 2013; 13:23.
73. Ahmed TA, Hayslip J, Leggas M. Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leuk Res 2014; 38:1350-7.
74. Wennerberg K, Rossman KL, Der CJ. The RAS superfamily at a glance. J Cell Sci 2005; 118:843-6.
75. Sun J, Singh V, Lau A, et al. Mycobacterium tuberculosis nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity. PLoS Pathog 2013; 9:e1003499.
76. Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 2014; 5:e29846.
77. Wang J, Yang K, Zhou L, et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 2013; 9:e1003697.
78. Aizman E, Blacher E, Ben-Moshe O, Kogan T, Kloog Y, Mor A. Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines. Clin Exp Immunol 2014; 175:458-67.
79. Silva-Garciá O, Valdez-Alarcón JJ, Baizabal-Aguirre VM. The Wnt/-catenin signaling pathway controls the inflammatory response in infections caused by pathogenic bacteria. Mediators Inflamm 2014; doi:10.1155/2014/310183.
80. Zhang Y, Pizzute T, Pei M. A review of crosstalk between MAPK and Wnt signals and its impact on cartilage regeneration. Cell Tissue Res 2014; 358:633-49.
81. Blumenthal A, Ehlers S, Lauber J, et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006; 108:965-73.
82. Schaale K, Brandenburg J, Kispert A, Leitges M, Ehlers S, Reiling N. Wnt6 is expressed in granulomatous lesions of Mycobacterium tuberculosis-infected mice and is involved in macrophage differentiation and proliferation. J Immunol 2013; 191:5182-95.
83. Wu X, Deng G, Hao X, et al. A caspase-dependent pathway is involved in Wnt/-catenin signaling promoted apoptosis in bacillus Calmette-Guerin infected RAW264.7 macrophages. Int J Mol Sci 2014; 15: 5045-62.
84. Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, Mc-Kenna SL. Induction of autophagy by imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol 2013; 88:455-62.
85. Bruns H, Stegelmann F, Fabri M, et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J Immunol 2012; 189: 4069-78.
86. Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA 2015; 112: 1827-32.
87. Sundberg TB, Choi HG, Song JH, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci USA 2014; 111:12468-73.
88. Hardie DG. AMPK-sensing energy while talking to other signaling pathways. Cell Metab 2014; 20:939-52.
89. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014; 20:953-66.
90. Hur KY, Lee MS. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig 2015; doi:10.1111/jdi.12328.
91. Blagih J, Coulombe F, Vincent EE, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 2015; 42:41-54.
92. Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B, Cantrell DA. AMPK1: A glucose sensor that controls CD8 T-cell memory. Eur J Immunol 2013; 43:889-96.
93. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89-118.
94. Tsubaki M, Takeda T, Sakamoto K, et al. Bisphosphonates and statins inhibit expression and secretion of MIP-1 via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways. Am J Cancer Res 2015; 5:168-79.
95. Wei YM, Li X, Xu M, et al. Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Cell Physiol Biochem 2013; 31:925-37.
96. Skerry C, Pinn ML, Bruiners N, Pine R, Gennaro ML, Karakousis PC. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 2014; 69:2453-7.
97. Imai S. The NAD World: a new systematic regulatory network for metabolism and aging-Sirt1, systemic NAD biosynthesis and their importance. Cell Biochem Biphys 2009; 53:65-74.
98. Cantó C, Sauve AA, Bai P. Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol Aspects Med 2013; 34: 1168-201.
99. Wei W, Graeff R, Ye J. Roles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca2+ signaling pathway. World J Biol Chem 2014; 26:58-67.
100. Haffner CD, Becherer JD, Boros EE. Discovery, synthesis, and biological evaluation of thiazoloquin(az)olin(on)es as potent CD38 inhibitors. J Med Chem 2015; 58:3548-71.
101. Schreiber V, Dantzer F, Amé JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28.
102. Leung A, Todorova T, Ando Y, Chang P. Poly(ADP-ribose) regulates post-transcriptional gene regulation in the cytoplasm. RNA Biol 2012; 9:542-8.
103. Bai P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell 2015; 58:947-58.
104. Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in Inflammatory diseases. Am J Pathol 2011; 178:946-55.
105. Cohen-Armon M. PARP-1 activtion in the ERK signaling pathway. Trends Pharmacol Sci 2007; 28:556-60.
106. Racz B, Hanto K, Tapodi A, et al. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation. Free Radic Biol Med 2010; 49:1978-88.
107. Zheng L, Szabó C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-B. Diabetes 2004; 53:2960-7.
108. Nossa CW, Blanke SR. Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health. Gut Microbes 2010; 1:373-8.
109. Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol 2013; 3:290.
110. Martire S, Mosca L, d'Erme M. PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases. Mech Ageing Dev 2015; 146:53-64.
111. Gerace E, Masi A, Resta F. PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA receptors. Neurobiol Dis 2014; 70:43-52.
112. Cheng XL, Ding F, Li H, et al. Activation of AMPA receptor promotes TNF-release via the ROS-cSrc-NFB signaling cascade in RAW264.7. Biochem Biophys Res Commun 2015; 461:275-80.
113. Ba X, Gupta S, Davidson M, Garg NJ. Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes. J Biol Chem 2010; 285: 11596-606.
114. Afriat R, Horowitz S, Priel E. Mycoplasma fermentans inhibits the activity of cellular DNA topoisomerase I by activation of PARP1 and alters the efficacy of its anti-cancer inhibitor. PLoS One 2013; 8:72377.
115. Yu H, Schwarzer K, Förster M, et al. Role of high-mobility group box 1 protein and poly(ADP-ribose) polymerase 1 degradation in Chlamydia trachomatis-induced cytopathicity. Infect Immun 2010; 78:3288-97.
116. Atasheva S, Frolova EI, Frolov I. Interferon-stimulated poly (ADP-ribose) polymerases are potent inhibitors of cellular translation and virus replication. J Virol 2014; 88:2116-30.
117. Daugherty MD, Young JM, Kerns JA, Malik HS. Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts. PLoS Genet 2014; 10:e1004403.
118. Sun J, Siroy A, Lokareddy RK, et al. The tuberculosis necrotizing toxin kills macrophages by hydrolyzing NAD. Nat Struct Mol Biol 2015; doi:10.1038/nsmb.3064.
119. Chandrasekaran S, Caparon MG. The Streptococcus pyogenes NAD+ glycohydrolase modulates epithelial cell PARylation and HMGB1 release. Cell Microbiol 2015; doi:10.1111/CMI.12442.
120. Hernandez-Pando R, Barrios-Payan J, Mata-Epinosa D, et al. The role of High Mobility Group Box 1 protein (HMGB1) in the immunopathology of experimental pulmonary tuberculosis. PLoS One 2015; 10:e0133200.
121. Wu X, Deng G, Li M, et al. Wnt/-Catenin signaling reduces bacillus Calmette-Guerin-induced macrophage necrosis through a ROS-mediated PARP/AIF-dependent pathway. BMC Immunol 2015; 16:16.
122. Sambucci M, Laudisi F, Novelli F, Bennici E, Rosado MM, Pioli C. Effects of PARP-1 deficiency on Th1 and Th2 cell differentiation. Sci World J 2013; doi:10.1155/2013/375024.
123. Zhang P, Maruyama T, Konkel JE, et al. PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS One 2013; 8:e71590.
124. US Food and Drug Administration. FDA approves Lynparza to treat advanced ovarian cancer. Available at: http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm427554.htm. Accessed 13 August 2015.
125. Ahmad SF, Attia SM, Zoheir KM, Ashour AE, Bakheet SA. Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment. Int Immunopharmacol 2014; 19:52-9.
126. Martínez-Redondo P, Vaquero A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer 2013; 4:148-63.
127. Gerhart-Hines Z, Dominy JE Jr, Blättler SM, et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD+. Mol Cell 2011; 44:851-63.
128. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol Mech Dis 2010; 5:253-95.
129. Bosch-Presegué L, Vaquero A. Sirtuin-dependent epigenetic regulation in the maintenance of genome integrity. FEBS J 2014; 282:1745-67.
130. Liu G, Bi Y, Xue L, et al. Dendritic cell SIRT1-HIF1 axis programs the differentiation of CD4+ T cells through IL-12 and TGF-1. Proc Natl Acad Sci USA 2015; 112:E957-65.
131. Hwang JW, Yao H, Caito S, Sundar IK, Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 2013; 61:95-110.
132. Turkmen K, Karagoz L, Kucuk A. Sirtuins as novel players in the pathogenesis of diabetes mellitus. World J Diabetes 2014; 5:894-900.
133. Guarente L. Sirtuins, aging, and medicine. New Engl J Med 2011; 364:2235-44.
134. Vachharajani VT, Liu T, Brown CM, et al. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. J Leukoc Biol 2014; 96:785-96.
135. Liu TF, Vachharajani V, Millet P, Bharadwaj MS, Molina AJ, McCall CE. Sequential actions of SIRT1-RELB-SIRT3 coordinate nuclear mitochondrial communication during immunometabolic adaptation to acute inflammation and sepsis. J Biol Chem 2015; 290:396-408.
136. Alvarez Y, Rodríguez M, Municio C, et al. Sirtuin 1 is a key regulator of the interleukin-12 p70-interleukin-23 balance in human dendritic cells. J Biol Chem 2012; 287:35689-701.
137. Gao B, Kong Q, Kemp K, Zhao YS, Fand D. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2 mediated reversal of T-cell tolerance. Proc Natl Acad Sci USA 2012; 109:899-904.
138. Koyuncu E, Budayeva HG, Miteva YV, et al. Sirtuins are evolutionarily conserved viral restriction factors. mBio 2014; 5:e02249-14.
139. Kwon HS, Brent MM, Getachew R, et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008; 3:158-67.
140. Martin C, Leyton L, Arancibia Y, et al. Modulation of the AMPK/Sirt1 axis during neuronal infection by herpes simplex virus type 1. J Alzheimers Dis 2014; 42:301-12.
141. Eskandarian HA, Impens F, Nahori MA, et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science 2013; 341:1238858.
142. Moreira D, Rodrigues V, Abengozar M, et al. Leishmania infantum modulates host macrophage mitochondrial metabolism by hijacking the SIRT1-AMPK axis. PLoS Pathog 2015; 11:e1004684.
143. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phospodiesterases. Cell 2012; 148:421-33.
144. Mitchel SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 ACTIVATOR srt1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 2014; 6:836-43.
145. Mouchiroud L, Houtkooper RH, Auwerx J. NAD+ metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013; 48:397-408.
146. Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab 2013; 15(suppl 3):26-33.
147. Mao Z, Hine C, Tian X, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332:1443-6.
148. Bolivar B, Welch JT. Understanding PZA's host directed activity [abstract J3 1017]. In: Program and Abstracts of the Host Response in Tuberculosis Symposium (Santa Fe). Silverthorne: Keystone Symposia on Molecular and Cellular Biology, 2015:76.
149. Gongol B, Marin T, Peng IC, et al. AMPK2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6. Proc Natl Acad Sci USA 2013; 110:3161-6.
150. Ruderman NB, Xu XJ, Nelson L, et al. AMPK and SIRT1: a longstanding partnership Am J Physiol Endocrinol Metab 2010; 298: E751-60.
151. Kuijl C, Savage ND, Marsman M, et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 2007; 450:725-30.
152. Barrett JP, Minogue AM, Falvey A, Lynch MA. Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages. Exp Cell Res 2015; 335:258-68.
153. Rocher C, Singla DK. SMAD-PI3K-Akt-mTOR pathway mediates BMP-7 polarization of monocytes into M2 macrophages. PLoS One 2013; 8:e84009.
154. Zhai C, Cheng J, Mujahid H, et al. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. PLoS One 2014; 9:390563.
155. Hindupur SK, Gonzalez A, Hall MN. The opposing actions of target of rapamycin and AMP-activated protein kinase in cell growth control. Cold Spring Harb Perspect Biol 2015; 7:a019141.
156. Zhang Z, Amorosa LF, Coyle SM, et al. Proteolytic cleavage of AMPKalpha and intracellular MMP9 expression are both required for TLR4-mediated mTORC1 activation and HIF-1alpha expression in leukocytes. J Immunol 2015; 195:10-4049.
157. Zullo AJ, Jurcic Smith KL, Lee S. Mammalian target of rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages. BMC Biochem 2014; 15:4.
158. Kamphorst AO, Araki K, Ahmed R. Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. Vaccine 2015; 33(suppl 2):B21-8.
159. Jagannath C, Bakhru P. Rapamycin-induced enhancement of vaccine efficacy in mice. Methods Mol Biol 2012; 821:295-303.
160. Üstün S, Lassnig C, Preitschopf A, et al. Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. Transpl Immunol 2015; 33:45-50.
161. Li N, Qin J, Lan L, et al. PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer Biol Ther 2015; 16:297-306.
162. Li L, Ng DS, Mah WC, et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death Differ 2015; 22:1081-93.
163. Sui X, Han W, Pan H. p53-induced autophagy and senescence. Oncotarget 2015; 6:11723-4.
164. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13:283-96.
165. Huang G, Redelman-Sidi G, Rosen N, Glickman MS, Jiang X. Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem 2012; 287:23196-202.
166. Kim SA, Choi HC. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun 2012; 425:866-72.
167. Holla S, Ghorpade DS, Singh V, Bansal K, Balaji KN. Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-induced apoptosis. Mol Cancer 2014; 13:210.
168. Bradfute SB, Castillo EF, Arko-Mensah J, et al. Autophagy as an immune effector against tuberculosis. Curr Opin Microbiol 2013; 16: 355-65.
169. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell 2014; 159:1263-76.
170. Ng F, Tang BL. Sirtuins' modulation of autophagy. J Cell Physiol 2013; 228:2262-70.
171. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015; 6:456-80.
172. Victorino VJ, Pizzatti L, Michelletti P, Panis C. Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle. Curr Med Chem 2014; 21:3211-26.
173. Alfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotechnol 2012; doi:10.1155/2012/936486.
174. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 29:44-8.
175. Kwiatkowska S, Piasecka G, Zieba M, Piotrowski W, Nowak D. Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis. Respir Med 1999; 93:272-6.
176. Lamsal M, Gautam N, Bhatta N, Toora BD, Bhattacharya SK, Baral N. Evaluation of lipid peroxidation product, nitrite and antioxidant levels in newly diagnosed and two months follow-up patients with pulmonary tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38:695-703.
177. Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity. Annu Rev Immunol 2015; 33:51-531.
178. Seimon TA, Kim MJ, Blumenthal A, et al. Induction of ER stress in macrophages of tuberculosis granulomas. PLoS One 2010; 5:e12772.
179. Lim YJ, Choi JA, Choi HH, et al. Endoplasmic reticulum stress pathway-mediated apoptosis in macrophages contributes to the survival of Mycobacterium tuberculosis. PLoS One 2011; 6:e28531.
180. Choi JA, Lim YJ, Cho SN, et al. Mycobacterial HBHA induces endoplasmic reticulum stress-mediated apoptosis through the generation of reactive oxygen species and cytosolic Ca2+ in murine macrophage RAW 264.7 cells. Cell Death Dis 2013; 4:e957.
181. Choi HH, Shin DM, Kang G, et al. Endoplasmic reticulum stress response is involved in Mycobacterium tuberculosis protein ESAT-6-mediated apoptosis. FEBS Lett 2010; 584:2445-54.
182. Lim YJ, Choi JA, Lee JH, Choi CH, Kim HJ, Song CH. Mycobacterium tuberculosis 38-kDa antigen induces endoplasmic reticulum stress-mediated apoptosis via toll-like receptor 2/4. Apoptosis 2015; 20:358-70.
183. Erstad DJ, Cusack JC Jr. Targeting the NF-B pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22:705-46.
184. Verhelst K, Verstrepen L, Carpentier I, Beyaert R. IB kinase (IKK): a therapeutic target in inflammation and cancer. Biochem Pharmacol 2013; 85:873-80.
185. Bhatt K, Verma S, Ellner JJ, Salgame P. Quest for correlates of protection against tuberculosis. Clin Vaccine Immunol 2015; 22: 258-66.
186. Thurnher M, Gruenbacher G. T lymphocyte regulation by mevalonate metabolism. Sci Signal 2015; 8:re4.
187. Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 2013; 13:621-34.
188. Mahajan S, Dkhar HK, Chandra V, et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPAR and TR4 for survival. J Immunol 2012; 188:5593-603.
189. Wang S, Sun Z, Zhang X, et al. Wnt1 positively regulates CD36 expression via TCF4 and PPAR in macrophages. Cell Physiol Biochem 2015; 35:1289-302.
190. Yao S, Miao C, Tian H, et al. Endoplasmic reticulum stress promotes macrophage-derived foam cell formation by up-regulating cluster of differentiation 36 (CD36) expression. J Biol Chem 2014; 289:4032-42.
191. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161:1527-38.
192. Wang X, Phillips MI, Mehta JL. LOX-1 and angiotensin receptors, and their interplay. Cardiovasc Drugs Ther 2011; 25:401-17.
193. Nakashima T, Umemoto S, Yoshimura K, et al. TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase. Hypertens Res 2015; doi:10.1038/hr.2015.55.
194. Palanismay GS, Kirk NM, Ackart DF, et al. Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infection in guinea pigs. PLoS One 2012; 7:e34148.
195. Hawkes M, Li X, Crockett M, et al. CD36 deficiency attenuates experimental mycobacterial infection. BMC Infect Dis 2010; 10:299.
196. Christakos S, Seth T, Hirsch J, Porta A, Moulas A, Dhawan P. Vitamin D biology revealed through the study of knockout and transgenic mouse models. Annu Rev Nutr 2013; 33:71-85.
197. Riek AE, Oh J, Sprague JE, et al. Vitamin D suppression of endoplasmic reticulum stress promotes an antiatherogenic monocyte/macrophage phenotype in type 2 diabetic patients. J Biol Chem 2012; 287:38482-94.
198. Larriba MJ, González-Sancho JM, Bonilla F, Munõz A. Interaction of vitamin D with membrane-based signaling pathways. Front Physiol 2014; 5:60.
199. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6:231-43.
200. Daley P, Jagannathan V, John KR, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015; 15:528-34.
201. Raqib R, Mily A, Kamal SM, et al. Clinical trial of oral phenylbutyrate and vitamin D adjunctive therapy in pulmonary tuberculosis in Bangladesh [abstract OAP-257-30]. In: Program and Abstracts Of the 45th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Barcelona, 28 October-1 November 2014. Paris: The Union, 2014:S233-4.
202. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
203. Gregor MF, Hotamisligi GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29:415-45.
204. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014; 44:617-26.
205. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis 2013; 93:S10-4.
206. Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther 2014; 28:425-32.
207. Dai W, Wang X, Ding Z, Dai D, Mehta JL. DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway. Acta Diabetol 2014; 51:471-8.
208. Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol 2015; 16:850-8.
209. Cardoso F, Castro F, Moreira-Teixeria L, et al. Myeloid sirtuin 2 expression does not impact long-term Mycobacterium tuberculosis control. PLoS One 2015; 10:e0131904.
210. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793-5.